<DOC>
	<DOCNO>NCT02407912</DOCNO>
	<brief_summary>To assess effect toxicity intrapleural administration hypertonic cisplatin malignant pleural effusion patient non-small-cell lung cancer .</brief_summary>
	<brief_title>Cisplatin Malignant Pleural Effusion Patients With Non-small-cell Lung Cancer</brief_title>
	<detailed_description>The lung fully expand thoracostomy use chest tube double lumen , patient enrol trial.First , premedication include antiemetic hydration perform . Thereafter , 75 mg body surface area cisplatin 50 ml distil water inject chest tube.The patient ask change position ( supine bilateral decubital ) time time 30 minute . The chest tube clamp 48 h tube declamped allow drain . When drainage effusion le 100 ml day , chest tube remove . Any patient whose drainage effusion continue 2 week withdraw trial also judge nonresponder .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Cytologically proven previously untreated malignant pleural effusion Nonsmallcell Lung Cancer ; An Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 ; A leucocyte count of≥4000µl ; A platelet count of≥100000µl ; A normal creatinine level ; Serum glutamic oxaloacetic transaminase/glutamic pyruvic transaminase level twice upper limit normal ; Survival time ≥12 week . Previously treat malignant pleural effusion ; Pericardial effusion； Pregnant； Uncontrolled hypertension diabetes； Liver cihrosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>